Characteristics of NHL and HR B-CLL patients
| Patient no. . | Sex . | Age, y . | Year* . | Diagnosis† (stage) . | Prior therapy‡ . | Off therapy,§ mo . | Chromosomeabnormality‖ . | Lymphocytes,¶ ×109/L(no. of CD3+ cells) . |
|---|---|---|---|---|---|---|---|---|
| 01 | M | 82 | 2003 | FL (IIIB) | GEOX | 12 | t(14;18) | 1.7 (1.1) |
| 02 | M | 60 | 2002 | FL (IVA) | None | — | None | 2.4 (1.9) |
| 03 | F | 76 | 2002 | FL (II) | (VACOP-B) | 24 | t(14;18) | 2.1 (1.4) |
| 04 | F | 56 | 1999 | FL (IB) | Flu/Ctx/Nov | 24 | None | 2.2 (1.7) |
| 05 | F | 64 | 2002 | FL (IVA) | None | — | None | 2.9 (2.7) |
| 06 | M | 57 | 2000 | FL (IIB) | (FEN) | — | t(14;18); t(8;14) | 1.8 (2.2) |
| 07 | F | 50 | 2004 | FL (IVB) | None | — | None | 1.6 (1.3) |
| 08 | M | 52 | 2004 | FL (II) | VP | 6 | None | 4.3 (3.2) |
| 09 | F | 70 | 2004 | FL (IIIs) | None | — | None | 3.2 (2.3) |
| 10 | F | 64 | 2002 | FL (IVA) | Flu/Ctx/Nov | 36 | t(14;18) | 1.8 (1.0) |
| 11 | F | 57 | 1995 | FL (III) | MACOP-B | 48 | None | 3.8 (2.6) |
| 12 | M | 42 | 2002 | FL (III) | (MACOP-B) | — | None | 4.8 (2.6) |
| 13 | F | 58 | 2004 | FL (II) | (IEV) | — | None | 3.9 (2.2) |
| 14 | M | 53 | 2004 | FL (IVA) | None | — | None | 3.4 (2.3) |
| 15 | F | 60 | 2003 | FL (I) | None | — | None | 2.3 (1.7) |
| 16 | M | 58 | 2004 | MT (IVA) | (FEN + MT) | — | t(14;18) | 2.9 (2.0) |
| 17 | F | 56 | 2004 | MT (II) | None | — | None | 3.1 (2.2) |
| 18 | M | 55 | 2004 | MT (II) | None | — | None | 3.2 (2.1) |
| 19 | M | 58 | 2003 | MT (II) | (IEV) | — | t(14;18) | 2.9 (1.9) |
| 20 | F | 62 | 2004 | MZ (II) | None | — | None | 3.6 (2.8) |
| 21 | F | 70 | 1997 | MZ (IVA) | (GEOX) | — | None | 2.6 (1.6) |
| 22 | F | 60 | 2004 | MZ (IVA) | (IEV) | — | t(14;18) | 3.2 (2.2) |
| 23 | M | 58 | 2003 | MZ (I) | None | — | None | 3.4 (2.4) |
| 24 | M | 62 | 2001 | DLCL | VACOP-B | 36 | None | 3.8 (2.6) |
| 25 | F | 49 | 2004 | DLCL | FEN + MT | 14 | t(14;18) | 2.7 (2.1) |
| 26 | F | 71 | 2004 | DLCL | VACOP-B + MT | 6 | None | 2.5 (1.7) |
| 27 | M | 57 | 2004 | DLCL | (VACOP-B) | — | t(14;18); t(3;14) | 1.9 (1.2) |
| 28 | M | 60 | 1998 | B-CLL (HR) | None | — | ND | 10.9 (1.9) |
| 29 | F | 64 | 1999 | B-CLL (HR) | None | — | ND | 9.8 (1.8) |
| 30 | F | 65 | 2002 | B-CLL (HR) | None | — | ND | 33.4 (4.6) |
| 31 | M | 61 | 2001 | B-CLL (HR) | Flu/Ctx | 10 | ND | 18.9 (1.8) |
| 32 | F | 56 | 1999 | B-CLL (HR) | None | — | ND | 41.5 (3.6) |
| 33 | M | 60 | 2001 | B-CLL (HR) | Flu | 12 | ND | 46.8 (4.1) |
| 34 | M | 65 | 2000 | B-CLL (HR) | None | — | ND | 68.5 (3.6) |
| 35 | M | 50 | 1999 | B-CLL (HR) | None | — | ND | 40.2 (2.8) |
| 36 | F | 59 | 2003 | B-CLL (HR) | None | — | ND | 15.6 (2.9) |
| 37 | M | 62 | 2003 | B-CLL (HR) | None | — | ND | 28.8 (5.9) |
| Patient no. . | Sex . | Age, y . | Year* . | Diagnosis† (stage) . | Prior therapy‡ . | Off therapy,§ mo . | Chromosomeabnormality‖ . | Lymphocytes,¶ ×109/L(no. of CD3+ cells) . |
|---|---|---|---|---|---|---|---|---|
| 01 | M | 82 | 2003 | FL (IIIB) | GEOX | 12 | t(14;18) | 1.7 (1.1) |
| 02 | M | 60 | 2002 | FL (IVA) | None | — | None | 2.4 (1.9) |
| 03 | F | 76 | 2002 | FL (II) | (VACOP-B) | 24 | t(14;18) | 2.1 (1.4) |
| 04 | F | 56 | 1999 | FL (IB) | Flu/Ctx/Nov | 24 | None | 2.2 (1.7) |
| 05 | F | 64 | 2002 | FL (IVA) | None | — | None | 2.9 (2.7) |
| 06 | M | 57 | 2000 | FL (IIB) | (FEN) | — | t(14;18); t(8;14) | 1.8 (2.2) |
| 07 | F | 50 | 2004 | FL (IVB) | None | — | None | 1.6 (1.3) |
| 08 | M | 52 | 2004 | FL (II) | VP | 6 | None | 4.3 (3.2) |
| 09 | F | 70 | 2004 | FL (IIIs) | None | — | None | 3.2 (2.3) |
| 10 | F | 64 | 2002 | FL (IVA) | Flu/Ctx/Nov | 36 | t(14;18) | 1.8 (1.0) |
| 11 | F | 57 | 1995 | FL (III) | MACOP-B | 48 | None | 3.8 (2.6) |
| 12 | M | 42 | 2002 | FL (III) | (MACOP-B) | — | None | 4.8 (2.6) |
| 13 | F | 58 | 2004 | FL (II) | (IEV) | — | None | 3.9 (2.2) |
| 14 | M | 53 | 2004 | FL (IVA) | None | — | None | 3.4 (2.3) |
| 15 | F | 60 | 2003 | FL (I) | None | — | None | 2.3 (1.7) |
| 16 | M | 58 | 2004 | MT (IVA) | (FEN + MT) | — | t(14;18) | 2.9 (2.0) |
| 17 | F | 56 | 2004 | MT (II) | None | — | None | 3.1 (2.2) |
| 18 | M | 55 | 2004 | MT (II) | None | — | None | 3.2 (2.1) |
| 19 | M | 58 | 2003 | MT (II) | (IEV) | — | t(14;18) | 2.9 (1.9) |
| 20 | F | 62 | 2004 | MZ (II) | None | — | None | 3.6 (2.8) |
| 21 | F | 70 | 1997 | MZ (IVA) | (GEOX) | — | None | 2.6 (1.6) |
| 22 | F | 60 | 2004 | MZ (IVA) | (IEV) | — | t(14;18) | 3.2 (2.2) |
| 23 | M | 58 | 2003 | MZ (I) | None | — | None | 3.4 (2.4) |
| 24 | M | 62 | 2001 | DLCL | VACOP-B | 36 | None | 3.8 (2.6) |
| 25 | F | 49 | 2004 | DLCL | FEN + MT | 14 | t(14;18) | 2.7 (2.1) |
| 26 | F | 71 | 2004 | DLCL | VACOP-B + MT | 6 | None | 2.5 (1.7) |
| 27 | M | 57 | 2004 | DLCL | (VACOP-B) | — | t(14;18); t(3;14) | 1.9 (1.2) |
| 28 | M | 60 | 1998 | B-CLL (HR) | None | — | ND | 10.9 (1.9) |
| 29 | F | 64 | 1999 | B-CLL (HR) | None | — | ND | 9.8 (1.8) |
| 30 | F | 65 | 2002 | B-CLL (HR) | None | — | ND | 33.4 (4.6) |
| 31 | M | 61 | 2001 | B-CLL (HR) | Flu/Ctx | 10 | ND | 18.9 (1.8) |
| 32 | F | 56 | 1999 | B-CLL (HR) | None | — | ND | 41.5 (3.6) |
| 33 | M | 60 | 2001 | B-CLL (HR) | Flu | 12 | ND | 46.8 (4.1) |
| 34 | M | 65 | 2000 | B-CLL (HR) | None | — | ND | 68.5 (3.6) |
| 35 | M | 50 | 1999 | B-CLL (HR) | None | — | ND | 40.2 (2.8) |
| 36 | F | 59 | 2003 | B-CLL (HR) | None | — | ND | 15.6 (2.9) |
| 37 | M | 62 | 2003 | B-CLL (HR) | None | — | ND | 28.8 (5.9) |
GEOX indicates gemcitabine, oxaliplatin, dexamethasone; VACOP-B, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; Flu/Ctx/Nov, fludarabine/cyclophosphamide/novobiocin; FEN, fludarabine, etoposide, mitoxantrone; VP, vincristine, prednisone; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; IEV, ifosfamide, etoposide, vincristine; MT, methotrexate; ND, not determined; and —, no therapy.
Year of diagnosis and staging.
Diagnosis and stage defined according to the REAL classification25 and the Rai modified classification.27
Chemotherapy. Therapy started after this study is indicated in the parentheses.
Time from the last cycle of chemotherapy and the time of this study.
Translocations: t(14;18), Bcl-2; t(3;14) Bcl-6; t(8;14) c-myc.28
Lymphocyte count at the time of the study.